Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12454178 | 0.98 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2CACNA1HKMT2ATDP1 | |
| SCHEMBL24926282 | 0.98 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2CACNA1HKMT2ATDP1 | |
| SCHEMBL24926262 | 0.98 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2CACNA1HKMT2ATDP1 | |
| SCHEMBL18743780 | 0.96 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2CACNA1HKMT2ATDP1 | |
| SCHEMBL19079021 | 0.84 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2CACNA1HKMT2AMEN1 | |
| SCHEMBL22403854 | 0.84 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2CACNA1HKMT2AMEN1 | |
| SCHEMBL11930700 | 0.84 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2CACNA1HKMT2AMEN1 | |
| SCHEMBL8248140 | 0.84 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2CACNA1HKMT2AMEN1 | |
| SCHEMBL19248414 | 0.84 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2CACNA1HKMT2AMEN1 | |
| SCHEMBL1547058 | 0.82 | SIGMAR1 (0.63) | ALDH1A1SMN1; SMN2CACNA1HKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130909-A1 | HPK1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | TETRAPHASE PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20190151403-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. | 2019-05-23 | — | — | US | disclosed |
| US-9874575-B2 | Analysis of estradiol and analytes with phenolic OH using labeling chemistry and LC-MSMS workflow | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2018-01-23 | — | — | US | disclosed |
| US-9874575-B2 | Analysis of estradiol and analytes with phenolic OH using labeling chemistry and LC-MSMS workflow | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2018-01-23 | — | — | US | disclosed |
| US-20170334841-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| WO-2017122754-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL INHIBITOR | 日本ケミファ株式会社 | 2017-07-20 | — | — | WO | disclosed |
| US-9624166-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624166-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-8828988-B2 | 8-AZA tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20130296279-A1 | SUBSTITUTED TETRACYCLINES | CONCERT PHARMACEUTICALS INC. | 2013-11-07 | — | — | US | disclosed |
| US-8367654-B2 | 8-AZA tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120108569-A1 | 8-AZA Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130909-A1 | HPK1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE2, WEE1, HK1 | ALDH1A1 3279/4885SMN1; SMN2 4806/4885CACNA1H 4253/4885 |
| US-20130296279-A1 | SUBSTITUTED TETRACYCLINES | TET1, TET3, SLC10A2 | ALDH1A1 1432/4885SMN1; SMN2 480/4885CACNA1H 512/4885 |
| US-20190151403-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | MALT1, MYLK2, FKBP1B | ALDH1A1 2805/4885SMN1; SMN2 781/4885CACNA1H 274/4885 |
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | MCL1, ABL1, MALT1 | ALDH1A1 3787/4885SMN1; SMN2 2381/4885CACNA1H 2070/4885 |
| US-20170334841-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1A, TUBA1C | ALDH1A1 2768/4885SMN1; SMN2 3267/4885CACNA1H 638/4885 |
| US-20120108569-A1 | 8-AZA Tetracycline Compounds | TET1, TET3, HDAC8 | ALDH1A1 1323/4885SMN1; SMN2 3122/4885CACNA1H 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.